Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Jason-Winnike_2023
Jason Winnike, Study Director at Metabolon Shares Insights from the Launch of its Oxysterol Targeted Panel
Shots: Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features  He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer  The interview gives a profound understanding…
March 6, 2023
VIEWPOINTS_Zack Usilton_2023
Zack Usilton, Chief Development Officer at Senta Partners Shares Insights from their Partnership with Reston ENT to Expand its Network of ENT Practices
Shots:   Zack Usilton spoke about their partnerships with Reston ENT. He also elaborated on their past collaborations with some of the allergy groups He also spoke on how these alliances will help Senta Partners to expand its footprint across 57 locations in 5 states in the Mid-Atlantic region   The interview gives an understanding of Senta…
March 2, 2023
VIEWPOINTS_Laura Niklason_2023
Laura Niklason, Founder, President, and CEO of Humacyte Shares her Views from the HAV™ Coronary Artery Bypass Graft Data Presented at the AHA Scientific Sessions 2022
Shots:  Laura gave an overview of Human acellular vessels (HAV). She talked about the six-month results of the HAV in a non-human primate model of CABG presented at the annual American Heart Association (AHA) Scientific Sessions 2022  She also elaborated on the construction and development of the CABG model and how it treats blocked arteries…
February 28, 2023
VIEWPOINTS_Suresh Kannan_2023
Suresh Kannan, Chief Product Officer at Model N Shares Insights on the Fall 2022 Product Release of the Model N Revenue Cloud
Shots: Suresh Kannan discussed the latest semi-annual update to bring innovative revenue optimization and compliance solution for life sciences and high-tech innovators He elaborated on the Fall 2022 product release, providing customers with tools to improve automation, efficiency, and profitability during economic uncertainty along with streamlined pricing communication The interview gives an understanding of how…
February 16, 2023
VIEWPOINTS_Whitney Stewart_2023
Whitney Stewart, Director of Clinical Project Management at Curebase Shares Insights from the Release of a Publication with Digital Therapeutics Alliance
Shots:  Whitney gave a brief on the partnership of Curebase with Digital Therapeutics Alliance to provide fit-for-purpose evidence standard for DTx product regulatory, reimbursement, and clinical acceptance  Whitney also elaborated on the Fit-for-Purpose Evidentiary standards and talked about why  the DTx devices do not fit in the standards for medical devices by quoting some examples …
February 14, 2023
VIEWPOINTS_Nicolas Paquette-Lamontagne_2023
Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis
Shots:  Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting     Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials  This interview…
February 13, 2023
VIEWPOINTS_Dr. Philip M. Toleikis_2023
Dr. Philip M. Toleikis, President & CEO at Sernova Shares Insights on the Partnership with Evotec to Develop a ‘Functional Cure’ for Diabetes
Shots:  Dr. Philip shared his views on the collaboration of Sernova with Evotec for iPSC-Based Beta cell replacement therapy to develop and commercialize a ‘Functional Cure’ for diabetes.   He also gave an overview on the benefits of Evotec’s iPSC-based insulin-producing beta cells on the next generation of Sernova’s Cell Pouch System  The interview discusses about how Sernova…
February 7, 2023
VIEWPOINTS_John Gabrielson_2023
John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs
Shots:  John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders Under the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
February 2, 2023
Load more